Cas:1106295-93-5 2-Chloro-4-methoxy-5-pyrimidinecarbonitrile manufacturer & supplier

Chemical Name:2-Chloro-4-methoxy-5-pyrimidinecarbonitrile

CAS.NO:1106295-93-5

Synonyms:2-Chloro-4-methoxy-5-pyrimidinecarbonitrile;5-Pyrimidinecarbonitrile, 2-chloro-4-methoxy-;2-Chloro-4-methoxy-pyrimidine-5-carbonitrile

Molecular Formula:C₆H₄ClN₃O

Molecular Weight:169.568

HS Code:2933599090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:385.1±22.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.551

PSA:58.80000

Exact Mass:169.004288

LogP:1.52

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Chloro-4-methoxy-5-pyrimidinecarbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Chloro-4-methoxy-pyrimidine-5-carbonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Pyrimidinecarbonitrile, 2-chloro-4-methoxy- Use and application,2-Chloro-4-methoxy-5-pyrimidinecarbonitrile technical grade,usp/ep/jp grade.

Related News: The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data. 2-Chloro-4-methoxy-5-pyrimidinecarbonitrile manufacturer Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia. 2-Chloro-4-methoxy-5-pyrimidinecarbonitrile supplier Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday. 2-Chloro-4-methoxy-5-pyrimidinecarbonitrile vendor Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov. 2-Chloro-4-methoxy-5-pyrimidinecarbonitrile factory Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.